Precision medicine research at Karmanos comparing biomarker

A Barbara Ann Karmanos Cancer Institute clinical researcher and her team have received $16,000 to further research in precision medicine for breast cancer treatment. Common Citizen leadership delivered the check to Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams, in November 2023. Dr. Elayoubi and her team have made significant strides in studying biomarkers and tumor molecular characteristics that may predict sensitivity and

IN THE NEWS: Hibiscus BioVentures partners with Karmanos to boost cancer research

IN THE NEWS: What is leukemia? Symptoms, causes and treatment

Biomarker development in the precision medicine era: lung cancer

SHOP TALK Appointments, Promotions, Honors, Grants, & Other

IN THE NEWS: What is leukemia? Symptoms, causes and treatment

Tumor Agnostic Approval Targets BRAF V600E–Mutant Disease

Biomarker development in the precision medicine era: lung cancer

Efficacy of Platinum Rechallenge in Metastatic Urothelial

Lasting bond and exceptional care through genetic counseling leads to rekindled friendship decades later

Precision medicine research at Karmanos comparing biomarker

Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing

Example workflow for precision medicine. Multi-omics data are